Product Information
BUPRENORPHINE-NALOXONE 12-3 MG SL FILM is a generic product labeled by Ingenus Pharmaceuticals LLC, priced at $4.4856 per EA under NDC 50742036530. Its NADAC has been published 153 times since Nov 1, 2023.
FDA first approved this application on Jun 2, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12; 3 mg/1; mg/1
Manufacturer
Ingenus Pharmaceuticals LLCNDC
50742036530
Classification
Generic
Dosage Form
FILM
Route
BUCCAL; SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212756FDA Approved
6/2/2022
TE Code
AB
On Market Since
8/29/2023
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE-NALOXONE 12-3 MG SL FILM has been published 153 times since Nov 1, 2023, and over the history we have for it it has declined 24.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.4856 per EA |
|---|---|
| All-time high | $7.9464 (Dec 13, 2023) |
| All-time low | $3.8234 (Apr 17, 2024) |
| 52-week high | $4.4856 |
| 52-week low | $4.1480 |
| Median price | $4.4184 |
| Average price | $4.8830 |
| Largest weekly change | +62.0% (Aug 21, 2024) |
| Weeks tracked | 153 |
| Tracking since | Nov 1, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the buprenorphine and naloxone market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ingenus Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
buprenorphine and naloxone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE-NALOXONE 12-3 MG SL FILM?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 12-3 MG SL FILM, manufactured by Ingenus Pharmaceuticals LLC, is $4.4856 per EA (NDC 50742036530), effective Sep 30, 2026.
How has the price of BUPRENORPHINE-NALOXONE 12-3 MG SL FILM changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 12-3 MG SL FILM has declined 24.8%. It has been tracked across 153 weekly CMS publications since Nov 1, 2023.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 12-3 MG SL FILM?
Since Nov 1, 2023, the NADAC for BUPRENORPHINE-NALOXONE 12-3 MG SL FILM has ranged from a low of $3.8234 (Apr 17, 2024) to a high of $7.9464 (Dec 13, 2023), with a median of $4.4184 per EA.
Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 12-3 MG SL FILM?
No other NADAC-published product currently shares the active ingredient and strength of BUPRENORPHINE-NALOXONE 12-3 MG SL FILM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BUPRENORPHINE-NALOXONE 12-3 MG SL FILM?
BUPRENORPHINE-NALOXONE 12-3 MG SL FILM (NDC 50742036530) is labeled by Ingenus Pharmaceuticals LLC, and CMS classifies it as a generic product.